Last updated: July 29, 2026
Butabarbital sodium is an established barbiturate product with limited publicly indexed late-stage development activity and constrained, aging-market growth visibility. Public clinical-trial disclosures for new butabarbital-sodium programs are sparse, and the product’s competitive pressure typically centers on supply, formulary positioning, controlled-substance handling, and substitution within barbiturate and alternative sedative-hypnotic classes rather than on rapid modern “pipeline” expansion.
This report synthesizes the highest-signal items typically used for investment and licensing decisions: (1) clinical-trials status and discoverability, (2) commercial market structure and demand drivers, and (3) near-to-medium term market projection built on product-lifecycle behavior, regulatory continuity, and likely access pathways for generics and alternatives.
Is butabarbital sodium still in clinical trials, and what is the latest update?
Featured snippet answer: Publicly indexed, active late-stage clinical trials for butabarbital sodium appear limited; the product is widely treated as an established medicine rather than a current, high-visibility investigational candidate.
What trial registries show for new butabarbital-sodium studies
- ClinicalTrials.gov: Searches centered on “butabarbital sodium” and common spelling variants typically surface older or non-expanding records and do not show a clear, ongoing Phase 3 or registrational program trajectory (no consistent pattern of new pivotal studies with drug-specific identifiers).
- Other registries: Public visibility outside ClinicalTrials.gov is generally lower for older barbiturate products, so “absence of evidence” in registries translates into “absence of high-signal pipeline” rather than an evidence-based statement of inactivity across all jurisdictions.
Does butabarbital sodium have new investigational uses being tested?
- The dominant therapeutic positioning for butabarbital sodium historically aligns with short-term sedation/sleep and related CNS indications typical of barbiturate class products.
- Current trial visibility for barbiturates has shifted over time toward:
- rescue/adjunct settings,
- controlled-substance formulations with improved usability,
- or substitution toward non-barbiturate sedative-hypnotics.
- For butabarbital sodium specifically, the public pipeline signal is low, implying that any new development would likely be tied to formulation, dosing convenience, or supply continuity rather than new clinical endpoints.
How much clinical development is there for butabarbital sodium compared with other barbiturates?
Featured snippet answer: Barbiturate-class development has contracted materially in modern decades, and butabarbital sodium shows a profile consistent with legacy products rather than active global registrational programs.
Comparative discovery reality
- New barbiturate starts in recent years are limited and often fragmented by region, sponsor, and indication.
- Competitive modern sedative-hypnotic development concentrates on controlled-release designs, abuse-deterrent concepts, and non-barbiturate mechanisms.
- As a result, butabarbital sodium’s competitive set is less “pipeline competition” and more “therapy-class switching” and “formulary survival.”
What patents protect butabarbital sodium, and when do they expire?
Featured snippet answer: Patent estates for legacy barbiturates are typically out of primary composition control; residual IP often resides in formulation, specific salt/crystallinity, manufacturing, or method-of-use claims, with timelines largely dependent on the most recent reformulation filings.
Expected IP pattern for legacy barbiturates
- Many early composition-of-matter filings for barbiturates predate modern database completeness and have passed typical 20-year terms.
- If any enforceable exclusivity persists, it is more likely in:
- formulation patents (for example, controlled-release, improved stability, or excipient system),
- manufacturing-process patents (granulation, crystallization, yield improvements),
- method-of-use patents tied to a defined regimen.
Practical implication for R&D and licensing
- For business planning, the more relevant question is usually:
- whether there are still-in-force Orange Book-listed patents for the marketed dosage form(s), and
- whether any new NDA/BLA or supplement work introduced additional, later-expiring IP.
Because this request is limited to “clinical trials update, market analysis and projection,” this report focuses on lifecycle and access rather than attempting to assert a specific patent list without an Orange Book and docket-backed record.
What is the Orange Book status of butabarbital sodium?
Featured snippet answer: Butabarbital sodium is typically an older, already-marketed drug where Orange Book listing status depends on the specific listed NDA and dosage form; for many legacy products, exclusivity has largely run off and generics may exist.
How to interpret Orange Book for a legacy barbiturate
- If multiple NDA entries exist (different strengths, manufacturers, or packaging), exclusivity and patent timelines may vary by listing.
- For market-entry modeling:
- the number of listed patents,
- their expiration dates,
- and whether any are “sure to be infringed” by the likely ANDA label are the leading indicators.
Licensing and challenge risk
- When a product is off primary exclusivity, competitive entry risk shifts to:
- ANDA approval timing,
- manufacturing scale-up and stability,
- label acceptance,
- and controlled-substance schedule compliance.
Are there Paragraph IV challenges or generic entry risks for butabarbital sodium?
Featured snippet answer: For legacy barbiturates, the most material generic-entry risks typically stem from regulatory or manufacturing barriers rather than from fresh exclusivity-driven litigation.
Where generic pressure usually comes from
- Competing generic manufacturers can enter once:
- listed patents are expired or invalidated,
- or a workaround exists via formulation/process changes not captured by claims,
- and the ANDA is approved with acceptable bioequivalence.
What tends to delay entry
- Stability and shelf-life constraints for barbiturate salts.
- Controlled-substance distribution and forecast accuracy.
- Formulation reproducibility and impurity profiles under cGMP.
What is the market size for butabarbital sodium, and where does demand come from?
Featured snippet answer: Demand is concentrated in niche prescribing and institutional use rather than broad primary-market growth. Growth is typically supply- and formulary-driven with limited new prescriber adoption.
Market structure
- Target buyers: retail pharmacy chains, wholesalers to institutional facilities, and specialty pharmacies where controlled-substance compliance is operationally standardized.
- Prescriber mix: clinicians with familiarity in CNS sedatives and those managing chronic or historical regimens.
- Use patterns: for legacy sedative-hypnotics, demand often tracks:
- patient continuity,
- payer formularies,
- and availability rather than new uptake.
Key demand drivers
- Controlled-substance regulations and the ability to maintain reliable distribution.
- Substitution dynamics:
- switching from barbiturates to non-barbiturate hypnotics,
- or continued use among existing patient cohorts.
- Price competition intensity once generics are established.
- Supply continuity events, including manufacturing disruptions and CMO constraints.
How does butabarbital sodium compare commercially with non-barbiturate sedative-hypnotics?
Featured snippet answer: Non-barbiturate sedative-hypnotics dominate long-run growth and new uptake; butabarbital sodium is more likely to be a legacy option with demand stabilization rather than expansion.
Competitive set behavior
- Competing products often include:
- Z-drugs (where used),
- benzodiazepines and related agents,
- and other hypnotics with different safety and monitoring profiles.
- Barbiturate prescribing faces class-level preferences:
- overdose risk perception,
- monitoring requirements,
- and prescriber preference shifts over time.
Commercial implication
- Even if butabarbital sodium remains clinically used, market share tends to be maintained through continuity and access, not through growth marketing.
What is the pricing and reimbursement outlook for butabarbital sodium?
Featured snippet answer: Pricing is likely to remain low-to-moderate and sensitive to generic availability, with reimbursement driven by formulary status and controlled-substance handling costs rather than by premium differentiation.
How price behaves in legacy generics
- Once multiple generics exist, pricing compresses toward:
- lowest-available wholesale acquisition patterns,
- negotiated institutional rebates,
- and competitive tender dynamics.
Where price can hold
- If only a small number of suppliers exist.
- If formulation or manufacturing constraints reduce competition.
- If a brand or dominant generic retains formulary positioning.
Market projection for butabarbital sodium: base case through 2030
Featured snippet answer: The most probable trajectory is a stabilizing, low-growth market with periodic volatility driven by supply, formulary updates, and controlled-substance manufacturing capacity. Category-level substitution limits sustained volume growth.
Base case (most likely)
- Volume: stable to modest decline as older patient cohorts eventually discontinue or switch.
- Price: stable-to-softening under generic competition.
- Revenue: roughly flat to mild decline, with spikes during supply shortfalls.
Bear case
- Faster substitution toward non-barbiturate hypnotics.
- More manufacturing exits among small suppliers.
- Formulary step-therapy tightening for older sedatives.
Bull case
- Supply stabilization and broadened institutional use.
- Narrow formulation improvements that reduce shortages and improve predictability.
- Temporary shortages among alternatives that reallocate demand.
Which geographic markets matter most for butabarbital sodium commercialization?
Featured snippet answer: Commercial significance typically concentrates in jurisdictions with large institutional prescribing and established controlled-substance supply chains. In practice, the highest-volume planning region is usually the US unless constrained by distribution or availability.
US commercial considerations
- Controlled-substance schedule compliance and distribution.
- Wholesaler/IDN procurement patterns.
- PBM formulary positioning.
EU/UK dynamics
- Barbiturate availability and prescribing patterns vary.
- Regulatory fragmentation can influence supplier count and continuity.
What manufacturing and IP barriers affect market entry for butabarbital sodium?
Featured snippet answer: Manufacturing reproducibility, impurity control, and stability are typically the biggest practical barriers once primary exclusivity ends.
Process and quality risks
- Salt form consistency and crystallinity control.
- Degradation pathways over shelf-life.
- Bioequivalence for reformulations, if any.
Regulatory compliance costs
- Controlled-substance manufacturing and warehousing.
- Security and audit readiness for distribution.
Key Takeaways
- Butabarbital sodium shows a clinical-trials profile consistent with a legacy, established product, with limited publicly visible late-stage pipeline activity.
- Market demand is niche and continuity-driven, with growth constrained by class-level substitution toward non-barbiturate sedative-hypnotics.
- Near-to-medium term revenue is best modeled as stable to mild decline with supply-driven volatility.
- Competitive pressure is dominated by generic availability, formulary status, and manufacturing reliability, not by active IP-driven pipeline battles.
- Business planning should prioritize:
- supplier capacity risk,
- controlled-substance distribution readiness,
- and the likelihood of incremental substitutions within sedative-hypnotic formularies.
FAQs
- Why do barbiturates like butabarbital sodium face substitution pressure in sedative-hypnotic formularies?
- What operational risks do controlled-substance manufacturers face that can affect butabarbital sodium availability?
- How should wholesalers and IDNs model demand volatility for legacy sedative-hypnotics like butabarbital sodium?
- What formulation or manufacturing changes most often determine whether an ANDA for a legacy barbiturate is viable?
- How does supply continuity affect realized net pricing for controlled-substance generics such as butabarbital sodium?
References
- ClinicalTrials.gov. (n.d.). Butabarbital sodium (search results and record listings). https://clinicaltrials.gov/
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA and Orange Book databases. https://www.accessdata.fda.gov/scripts/cder/daf/ and https://www.accessdata.fda.gov/scripts/cder/ob/
